Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
September 30, 2026 4.218M
June 30, 2026 -3.124M
March 31, 2026 19.50M
December 31, 2025 -2.889M
September 30, 2025 8.59M
June 30, 2025 -59.15M
March 31, 2025 8.547M
December 31, 2024 27.77M
September 30, 2024 2.193M
June 30, 2024 0.74M
March 31, 2024 -13.73M
December 31, 2023 12.25M
September 30, 2023 -37.88M
June 30, 2023 17.18M
March 31, 2023 24.81M
December 31, 2022 2.322M
Date Value
September 30, 2022 14.51M
June 30, 2022 19.81M
March 31, 2022 16.73M
December 31, 2021 43.24M
September 30, 2021 35.70M
June 30, 2021 48.20M
March 31, 2021 3.474M
December 31, 2020 -6.648M
September 30, 2020 4.597M
June 30, 2020 -279.64M
March 31, 2020 0.00
December 31, 2019 0.023M
September 30, 2019 -0.036M
June 30, 2019 0.002M
March 31, 2019 -0.01M
December 31, 2018 -0.005M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -5.147M
Armata Pharmaceuticals, Inc. -0.091M
Voyager Therapeutics, Inc. 29.27M
Invivyd, Inc. -0.585M
Elicio Therapeutics, Inc. 0.00